OverviewSuggest Edit

CEL-SCI is a biotechnology company. It is involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases. The Company's core capabilities include: drug discovery, research, development and manufacturing of complex biological substances.
TypePublic
Founded1983
HQVienna, US
Websitecel-sci.com

Latest Updates

Job Openings6
Revenue (FY, 2014)$264 K(+66%)
Share Price (Oct 2020)$15 (-6%)
Cybersecurity ratingAMore

Key People/Management at CEL-SCI

Geert R. Kersten

Geert R. Kersten

Director and Chief Executive Officer
Eyal Talor

Eyal Talor

Chief Scientific Officer
Patricia B. Prichep

Patricia B. Prichep

Senior Vice President of Operations
Daniel Zimmerman

Daniel Zimmerman

Senior Vice President of Cellular Immunology
John Cipriano

John Cipriano

Senior Vice President of Regulatory Affairs
William Jones

William Jones

Vice President of Quality Assurance
Show more

CEL-SCI Office Locations

CEL-SCI has an office in Vienna
Vienna, US (HQ)
8229 Boone Blvd
Show all (1)

CEL-SCI Financials and Metrics

CEL-SCI Revenue

CEL-SCI's revenue was reported to be $264.03 k in FY, 2014
USD

Net income (Q2, 2020)

(9.0m)

EBIT (Q2, 2020)

(6.7m)

Market capitalization (19-Oct-2020)

579.4m

Closing stock price (19-Oct-2020)

15.0

Cash (31-Mar-2020)

14.3m

EV

577.3m
CEL-SCI's current market capitalization is $579.4 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

254.6k159.6k264.0k

General and administrative expense

6.7m6.6m7.0m10.6m13.8m6.5m5.8m7.8m8.0m

R&D expense

11.7m10.4m12.7m17.0m20.9m17.4m15.6m9.4m12.7m

Operating expense total

18.4m17.0m19.7m27.6m34.7m23.9m21.4m17.2m20.7m
Quarterly
USDQ3, 2011Q1, 2012Q2, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

77.4k

General and administrative expense

1.9m1.9m1.6m2.0m1.6m1.8m2.0m2.1m2.4m5.2m2.9m2.8m621.2k1.7m1.7m1.4m1.3m1.6m2.7m1.4m1.7m2.0m1.9m3.0m2.6m2.6m

R&D expense

2.9m2.5m2.6m2.9m2.5m3.8m4.0m4.2m4.5m4.9m5.0m5.7m5.1m4.6m4.8m3.5m6.6m3.2m2.3m3.0m2.4m3.1m2.5m2.3m4.2m4.4m

Operating expense total

4.8m4.3m4.2m4.9m4.2m5.5m6.0m6.2m6.9m10.1m7.9m8.5m5.8m6.3m6.5m5.0m7.9m4.8m5.0m4.3m4.2m5.2m4.5m5.3m6.8m7.0m
USDQ3, 2011

Financial Leverage

2.6 x
Show all financial metrics

CEL-SCI Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

CEL-SCI Online and Social Media Presence

Embed Graph

CEL-SCI News and Updates

CEL-SCI Frequently Asked Questions

  • When was CEL-SCI founded?

    CEL-SCI was founded in 1983.

  • Who are CEL-SCI key executives?

    CEL-SCI's key executives are Geert R. Kersten, Eyal Talor and Patricia B. Prichep.

  • Who are CEL-SCI competitors?

    Competitors of CEL-SCI include Forge Therapeutics, U.S. Stem Cell and Cannabis Sativa.

  • Where is CEL-SCI headquarters?

    CEL-SCI headquarters is located at 8229 Boone Blvd, Vienna.

  • Where are CEL-SCI offices?

    CEL-SCI has an office in Vienna.

  • How many offices does CEL-SCI have?

    CEL-SCI has 1 office.